- Home
- BWB vs PHAT Comparison
BWB vs PHAT Comparison
Compare BWB & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWB
- PHAT
- Stock Information
- Founded
- BWB 2005
- PHAT 2018
- Country
- BWB United States
- PHAT United States
- Employees
- BWB N/A
- PHAT N/A
- Industry
- BWB Major Banks
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- BWB Finance
- PHAT Health Care
- Exchange
- BWB Nasdaq
- PHAT Nasdaq
- Market Cap
- BWB 365.0M
- PHAT 415.7M
- IPO Year
- BWB 2018
- PHAT 2019
- Fundamental
- Price
- BWB $13.72
- PHAT $4.22
- Analyst Decision
- BWB Strong Buy
- PHAT Strong Buy
- Analyst Count
- BWB 2
- PHAT 4
- Target Price
- BWB $17.50
- PHAT $23.00
- AVG Volume (30 Days)
- BWB 47.3K
- PHAT 1.2M
- Earning Date
- BWB 04-23-2025
- PHAT 03-06-2025
- Dividend Yield
- BWB N/A
- PHAT N/A
- EPS Growth
- BWB N/A
- PHAT N/A
- EPS
- BWB 1.03
- PHAT N/A
- Revenue
- BWB $106,036,000.00
- PHAT $55,252,000.00
- Revenue This Year
- BWB $26.46
- PHAT $204.30
- Revenue Next Year
- BWB $12.13
- PHAT $126.98
- P/E Ratio
- BWB $13.48
- PHAT N/A
- Revenue Growth
- BWB N/A
- PHAT 8001.47
- 52 Week Low
- BWB $10.52
- PHAT $4.19
- 52 Week High
- BWB $16.00
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- BWB 42.87
- PHAT 34.94
- Support Level
- BWB $13.60
- PHAT $4.33
- Resistance Level
- BWB $14.19
- PHAT $5.25
- Average True Range (ATR)
- BWB 0.36
- PHAT 0.64
- MACD
- BWB -0.07
- PHAT -0.07
- Stochastic Oscillator
- BWB 17.47
- PHAT 1.25
About BWB Bridgewater Bancshares Inc.
Bridgewater Bancshares Inc offers retail and commercial loan and deposit services to customers within the Minneapolis-St. Paul-Bloomington, MN-WI Metropolitan Statistical Area. The company engages in providing a wide range of deposit and lending products. Its products and services include commercial deposits, loans, online business services, credit card, mobile banking, and remote deposit services.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.